FDA to suspend quality-control program for food testing due to staff cuts
The Food and Drug Administration (FDA) is suspending a quality-control program for its food-testing laboratories as a result of staff cuts at the Department of Health and Human Services (HHS), according to an internal email seen by Reuters.
The proficiency testing program of the FDA's Food Emergency Response Network is designed to ensure consistency and accuracy across the agency's network of about 170 labs that test food for pathogens and contaminants to prevent food-borne illness.
The firing and departure of as many as 20,000 HHS employees has upended public health research and disrupted the agency's work on areas like bird flu and drug reviews. Donald Trump hopes to slash as much as $40bn from HHS.
'Unfortunately, significant reductions in force, including a key quality assurance officer, an analytical chemist, and two microbiologists at FDA's Human Food Program Moffett Center have an immediate and significant impact on the Food Emergency Response Network (FERN) Proficiency Testing (PT) Program,' says the email sent on Tuesday from FERN's National Program Office and seen by Reuters.
The program will be suspended at least through 30 September and means the agency will be unable to do planned quality-control work around lab testing for the parasite cyclospora in spinach or the pesticide glyphosate in barley, among other tests, the email says.
'These PTs and Exercises are critical to demonstrating the competency and readiness of our laboratory network to detect and respond to food safety and food defense events,' the email says.
HHS did not immediately respond to a request for comment.
A former FDA official told CBS News: 'There's so much work to go around. And us duplicating their work just doesn't make sense.' The outlet further reported that the FDA is devising plans that would halt most of its routine food safety inspection work, citing multiple federal health officials.
According to the officials who spoke to the network under anonymity, the plans may need congressional action to fully fund, adding that some higher-risk routine food inspections would probably remain at the FDA.
Food safety laboratories rely on these types of tests to meet standards for accreditation, said a source familiar with the situation, who was not aware of other ready alternatives to the FDA to provide such testing.
Sign up to This Week in Trumpland
A deep dive into the policies, controversies and oddities surrounding the Trump administration
after newsletter promotion
The FDA in early April suspended an effort to improve its testing for bird flu in milk, cheese and pet food as a result of staff cuts.
In February, HHS announced plans to fire 5,200 probationary employees across various agencies including the National Institutes of Health, the FDA and the Centers for Disease Control and Prevention.
The same month, Jim Jones, the head of food division at the FDA, quit in protest against the staff cuts. At the time, Jones said: 'I was looking forward to working to pursue the department's agenda of improving the health of Americans by reducing diet-related chronic disease and risks from chemicals in food.'
He went on to add that the cuts would make it 'fruitless' to continue in his role under the Trump administration, which he said has 'disdain for the very people' needed to ensure food safety.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
7 minutes ago
- Reuters
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.
Daily Mail
3 hours ago
- Daily Mail
Urgent nationwide recall issued for millions of eggs that could KILL if eaten
Nearly 2million eggs are being recalled over fears they could be contaminated with a potentially deadly pathogen. The FDA revealed the recall of 1.7m brown cage-free and certified organic eggs this week that have already sickened 79 people and hospitalized 21. Sold by California-based August Egg Company, the eggs are reported to be contaminated with salmonella — a bacteria that kills about 420 Americans every year. The eggs were sold between February 29 and May 17 across seven states — California, Washington, Nevada, Arizona, Nebraska, Kentucky and New Jersey. But officials fear that some of the affected cartons could still be lurking in refrigerators, putting others at risk. No deaths have been reported to date. Customers are advised to throw out the recalled eggs or to return them to sellers for a full refund. A total of 29 branded egg packages were included in the recall, including brands like Raleys, Simple Truth and Sun Harvest. The packages have a Julian Date — time stamp indicating when they were packaged — between 32 and 126. The Julian Date can be found on the short side of the carton. Salmonella is killed by cooking eggs because the bacteria cannot survive temperatures above 140F (60C). But officials warn that cooking eggs sunnyside up is risky, saying this may lead to the top of the egg not being hot enough to kill the bacteria. An investigation linked the outbreak to the eggs after 27 out of 30 patients interviewed reported consuming them before falling ill. An inspection at the company's egg processing facility also detected salmonella at the factory — which was linked back to the outbreak. Salmonella can contaminate eggs in two ways: It can enter an egg while it is forming inside a hen, or after an egg has been laid when the bacteria gets onto the shell after contact with feces and penetrates the shell. If salmonella gets onto factor equipment, this can then spread it to multiple other eggs. Experts say that cooking eggs thoroughly — such as via boiling or frying — will kill salmonella, which cannot survive temperatures above 140F (60C). About 1.35million people are infected with salmonella in the US every year, estimates suggest, via consuming contaminated food or water. Symptoms begin six hours to six days after infection, and include diarrhea, stomach pain or cramps and nausea and vomiting. For many patients, the illness goes away on its own within a few days. But in severe cases, it can lead to persistent diarrhea, high fevers, aches, headaches and lethargy. In rare instances, the bacteria can also spread to other organs in the body — which can prove fatal. An infected patient may spread the bacteria to others via touching contaminated surfaces, officials warn.
Reuters
4 hours ago
- Reuters
NIH scientists speak out over estimated $12 billion in Trump funding cuts
June 9 (Reuters) - Dozens of scientists, researchers and other employees at the U.S. National Institutes of Health issued a rare public rebuke Monday criticizing the Trump administration for major spending cuts that 'harm the health of Americans and people across the globe,' politicize research and 'waste public resources.' More than 60 current employees sent their letter to NIH director Dr. Jay Bhattacharya, U.S. Health Secretary Robert F. Kennedy Jr. and members of Congress who oversee NIH. Bhattacharya is scheduled to testify Tuesday at the U.S. Senate appropriations committee about his agency's budget. Overall, more than 340 current and recently terminated NIH employees signed the letter, about 250 of them anonymously. In their letter, NIH staff members said the agency had terminated 2,100 research grants totaling about $9.5 billion and an additional $2.6 billion in contracts since President Donald Trump took office Jan. 20. The contracts often support research, from covering equipment to nursing staff working on clinical trials. These terminations "throw away years of hard work and millions of dollars" and put patient health at risk, the letter said. NIH clinical trials "are being halted without regard to participant safety, abruptly stopping medications or leaving participants with unmonitored device implants." Officials at the U.S. Department of Health and Human Services, which oversees NIH, didn't immediately respond to a request for comment. In prior remarks, Bhattacharya has pledged support for Kennedy's Make America Healthy Again agenda, and he has said that means focusing the federal government's "limited resources" directly on combating chronic diseases. At his Senate confirmation hearings in March, Bhattacharya said he would ensure scientists working at NIH and funded by the agency have the necessary resources to meet its mission. NIH is the world's largest public funder of biomedical research and has long enjoyed bipartisan support from U.S. lawmakers. The Trump administration has proposed cutting $18 billion, or 40%, from NIH's budget next year, which would leave the agency with $27 billion. Nearly 5,000 NIH employees and contractors have been laid off under Kennedy's restructuring of U.S. health agencies, according to NIH staff. Dr. Jenna Norton, a program director within NIH's division of kidney, urologic and hematologic diseases, was one of 69 current employees who signed the letter as of early Monday. She said speaking out publicly was worth the risk to her career and family. "I am much more worried about the risks of not speaking up," Norton said. "There are very real concerns that we're being asked to do likely illegal activities, and certainly unethical activities that breach our rules." About 20 NIH employees who were recently terminated as probationary workers or "subject to reductions in force" added their names to the letter. In the letter, Norton and other NIH employees asked Bhattacharya to restore grants that were delayed or terminated for political reasons, where officials ignored peer review to "cater to political whims." They wrote that Bhattacharya had failed to uphold his legal duty to spend congressionally appropriated funds. One program director at the NIH's National Cancer Institute, who asked not to be identified for fear of retaliation, said she has repeatedly been asked to cancel research grants for no valid reason and in violation of agency rules. She said she fears she could become the target of lawsuits from grantees challenging those decisions. Dr. Benjamin Feldman, a staff scientist and core director at NIH's Institute of Child Health and Human Development, said he and other researchers want to work with Bhattacharya on reversing the cuts and restoring the NIH as a "beacon for science around the world." "This is really a hit to the whole enterprise of biomedical research in the United States," Feldman said. Dr. Ian Morgan, a postdoctoral fellow at the NIH, signed the letter and said he has heard from university researchers about patients losing access to novel cancer treatments in clinical trials due to the uncertainty over NIH funding. He also worries about the long-term effect from gutting NIH's investment in basic science research that can lead to lifesaving treatments years later. The NIH employees, based in Bethesda, Maryland, named their dissent the "Bethesda Declaration," modeled after Bhattacharya's Great Barrington Declaration in 2020 that called on public health officials to roll back lockdowns during the COVID-19 pandemic. "Our hope is that by modeling ourselves after the Great Barrington Declaration that maybe he'll see himself in our dissent," Norton said.
